Horizon Therapeutics Public Limited Company (HZNP), Jazz Pharmaceuticals plc (JAZZ), Solar Capital Ltd. (SLRC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Horizon Therapeutics Public Limited Company (HZNP)
72.5% sales growth and 9.27% return on equity
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally.
Horizon Therapeutics Public Limited Company's sales growth this year is anticipated to be 27.7% and 25.8% for next year.
Year-on-year quarterly revenue growth declined by 3.8%, now sitting on 2.19B for the twelve trailing months.
Volume
Today's last reported volume for Horizon Therapeutics Public Limited Company is 1302020 which is 18.54% below its average volume of 1598380.
Horizon Therapeutics Public Limited Company's sales growth for the next quarter is 72.5%. The company's growth estimates for the current quarter and the next is 120% and negative -16.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.27%.
Volatility
Horizon Therapeutics Public Limited Company's last day, last week, and last month's current volatility was 0.93%, 1.59%, and 1.41%, respectively.
Horizon Therapeutics Public Limited Company's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.68% (day), 2.80% (last week), and 3.34% (last month), respectively.
Horizon Therapeutics Public Limited Company's Stock Yearly Top and Bottom Value
Horizon Therapeutics Public Limited Company's stock is valued at $93.64 at 14:22 EST, below its 52-week high of $98.33 and way above its 52-week low of $54.27.
Horizon Therapeutics Public Limited Company's Moving Average
Horizon Therapeutics Public Limited Company's value is higher than its 50-day moving average of $92.32 and above its 200-day moving average of $86.62.2. Jazz Pharmaceuticals plc (JAZZ)
40.7% sales growth and 15.69% return on equity
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.
Jazz Pharmaceuticals plc's sales growth this year is expected to be 31.8% and 21.4% for next year.
Year-on-year quarterly revenue growth grew by 13.6%, now sitting on 2.44B for the twelve trailing months.
Volume
Today's last reported volume for Jazz Pharmaceuticals plc is 406079 which is 40.16% below its average volume of 678640.
Jazz Pharmaceuticals plc's sales growth for the next quarter is 40.7%. The company's growth estimates for the present quarter and the next is a negative 8.1% and negative -24.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.69%.
Volatility
Jazz Pharmaceuticals plc's last day, last week, and last month's current volatility was 0.78%, 1.02%, and 1.32%, respectively.
Jazz Pharmaceuticals plc's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.16% (day), 2.22% (last week), and 2.64% (last month), respectively.
Jazz Pharmaceuticals plc's Stock Yearly Top and Bottom Value
Jazz Pharmaceuticals plc's stock is valued at $177.64 at 14:22 EST, under its 52-week high of $189.00 and way higher than its 52-week low of $103.46.
Jazz Pharmaceuticals plc's Moving Average
Jazz Pharmaceuticals plc's worth is under its 50-day moving average of $178.59 and above its 200-day moving average of $167.58.Previous days news about Jazz Pharmaceuticals plc(JAZZ)
According to MarketWatch on Thursday, 1 July, "Shares of Jazz Pharmaceuticals plc gained 3.5% in premarket trading on Thursday, the day after the Food and Drug Administration said it had approved the company's acute lymphocytic leukemia treatment Rylaze. "
3. Solar Capital Ltd. (SLRC)
15.3% sales growth and 13.47% return on equity
Solar Capital Ltd.
Solar Capital Ltd.'s sales growth this year is expected to be 17.6% and 7.3% for next year.
Year-on-year quarterly revenue growth grew by 9.1%, now sitting on 124.73M for the twelve trailing months.
Volume
Today's last reported volume for Solar Capital Ltd. is 54191 which is 67.89% below its average volume of 168749.
Solar Capital Ltd.'s sales growth for the next quarter is 15.3%. The company's growth estimates for the present quarter and the next is 8.8% and 14.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.47%.
Volatility
Solar Capital Ltd.'s last day, last week, and last month's current volatility was 0.05%, 0.42%, and 0.79%, respectively.
Solar Capital Ltd.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.87% (day), 1.40% (last week), and 1.54% (last month), respectively.
Solar Capital Ltd.'s Stock Yearly Top and Bottom Value
Solar Capital Ltd.'s stock is valued at $18.80 at 14:22 EST, under its 52-week high of $19.69 and way higher than its 52-week low of $15.08.
Solar Capital Ltd.'s Moving Average
Solar Capital Ltd.'s value is under its 50-day moving average of $18.88 and above its 200-day moving average of $18.43.4. Procter & Gamble (PG)
6.8% sales growth and 30.65% return on equity
Procter & Gamble's sales growth this year is anticipated to be 6.5% and 3.5% for next year.
Year-on-year quarterly revenue growth grew by 5.2%, now sitting on 74.87B for the twelve trailing months.
Volume
Today's last reported volume for Procter & Gamble is 4383420 which is 49.6% below its average volume of 8697160.
Procter & Gamble's sales growth for the next quarter is 6.8%. The company's growth estimates for the ongoing quarter and the next is a negative 6% and negative -0.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 30.65%.
Volatility
Procter & Gamble's last day, last week, and last month's current volatility was 0.23%, 0.61%, and 0.62%, respectively.
Procter & Gamble's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.90% (day), 1.23% (last week), and 1.15% (last month), respectively.
Procter & Gamble's Stock Yearly Top and Bottom Value
Procter & Gamble's stock is valued at $135.90 at 14:22 EST, under its 52-week high of $146.92 and way higher than its 52-week low of $120.88.
Procter & Gamble's Moving Average
Procter & Gamble's worth is above its 50-day moving average of $135.34 and above its 200-day moving average of $133.39.Previous days news about Procter & Gamble(PG)
According to Bloomberg Quint on Tuesday, 29 June, "From Unilever Plc to Procter & Gamble Co., companies have announced plans to raise prices in the near term."
According to Bloomberg Quint on Thursday, 1 July, "Electricity on the grid could come from non-renewables like coal, gas, or nuclear, so the certificates are used to showcase renewable generation -- key for companies from Alphabet Inc's Google to The Procter & Gamble Co. that have pledged to use 100% clean power for their operations. "
5. Suburban Propane Partners, L.P. (SPH)
5.5% sales growth and 22.43% return on equity
Suburban Propane Partners, L.P., through its subsidiaries, engages in the retail marketing and distribution of propane, fuel oil, and refined fuels.
Suburban Propane Partners, L.P.'s sales growth this year is expected to be 12.6% and 3.8% for next year.
Year-on-year quarterly revenue growth grew by 34%, now sitting on 1.22B for the twelve trailing months.
Volume
Today's last reported volume for Suburban Propane Partners, L.P. is 349312 which is 5.35% below its average volume of 369042.
Suburban Propane Partners, L.P.'s sales growth is a negative 0% for the current quarter and 5.5% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 68% and negative -7.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 22.43%.
Volatility
Suburban Propane Partners, L.P.'s last day, last week, and last month's current volatility was 0.27%, 0.45%, and 0.80%, respectively.
Suburban Propane Partners, L.P.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.82% (day), 1.28% (last week), and 1.69% (last month), respectively.
Suburban Propane Partners, L.P.'s Stock Yearly Top and Bottom Value
Suburban Propane Partners, L.P.'s stock is valued at $15.41 at 14:22 EST, way below its 52-week high of $18.18 and way higher than its 52-week low of $12.50.